Skip to main content

Table 5 Changes in liver function and HbA1c after pemafibrate treatment

From: Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Characteristic Weeks after pemafibrate treatment Pemafibrate treatment
Week −8 Week −4 Week 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 P* Baselinea Post-doseb P**
AST, median (IQR), IU/L             
 Total 21 (18–29) 22 (18–30) 23 (19–33) 21 (18–34) 23 (18–31) 24 (21–44) 23 (19–29) 22 (19–33) 21 (19–29) 0.9212 23 (18–31) 23 (19–31) 0.9139
 Increased LDL-C group (group I) 23 (19–34) 26 (21–33) 23 (20–36) 19 (18–32) 20 (17–33) 26 (21–48) 23 (18–40) 23 (20–43) 20 (19–22) 0.6619 23 (19–34) 21 (18–34) 0.3833
 No LDL-C increase group (group NI) 20 (17–27) 20 (17–29) 20 (18–29) 21 (19–35) 24 (19–28) 23 (21–40) 24 (20–28) 21 (17–49) 23 (16–34) 0.9440 20 (18–28) 25 (20–29) 0.6184
P*** 0.2611 0.1970 0.1894 0.4655 0.3690 0.6480 0.9545 0.5388 0.8421   0.2273 0.4646  
ALT, median (IQR), IU/L             
 Total 22 (18–36) 26 (18–37) 23 (18–40) 19 (16–29) 20 (17–27) 19 (17–58) 21 (16–31) 18 (15–23) 17 (15–24) 0.1297 24 (17–37) 19 (16–30) 0.0010
 Increased LDL-C group (group I) 28 (19–40) 30 (19–39) 31 (19–41) 19 (17–28) 20 (15–38) 19 (16–62) 23 (17–38) 19 (15–33) 18 (14–25) 0.1802 31 (21–40) 19 (16–34) 0.0040
 No LDL-C increase group (group NI) 22 (17–29) 23 (16–36) 20 (17–29) 19 (15–38) 20 (17–25) 17 (17–53) 21 (16–30) 18 (14–53) 17 (15–24) 0.9352 22 (17–29) 21 (17–26) 0.0909
P*** 0.1606 0.1605 0.0582 1.0000 0.9269 0.9091 0.5141 1.0000 0.8427   0.0520 0.9918  
γGTP, median (IQR), IU/L             
 Total 34 (26–94) 46 (28–83) 39 (24–92) 34 (21–48) 30 (18–47) 43 (31–74) 28 (15–57) 34 (20–57) 33 (20–65) 0.0656 37 (26–86) 31 (19–54) <0.0001
 Increased LDL-C group (group I) 43 (31–98) 67 (31–110) 53 (28–102) 39 (29–60) 32 (22–53) 53 (32–80) 37 (14–71) 40 (29–67) 38 (25–71) 0.2944 48 (28–101) 34 (26–75) < 0.0001
 No LDL-C increase group (group NI) 31 (20–77) 36 (24–63) 32 (18–54) 20 (12–49) 23 (17–34) 31 (14–44) 25 (16–47) 18 (13–46) 31 (15–49) 0.4730 30 (19–62) 26 (17–43) <0.0001
P*** 0.0975 0.0643 0.0382 0.1118 0.1074 0.0471 0.2486 0.0570 0.1392   0.0600 0.0992  
HbA1c, mean (SD), %             
 Total 7.5 (1.5) 7.7 (1.5) 7.4 (1.6) 7.6 (1.2) 7.4 (1.6) 7.2 (1.4) 7.2 (1.3) 7.9 (1.4) 7.1 (1.9) 0.7897 7.4 (1.4) 7.3 (1.5) 0.0502
 Increased LDL-C group (group I) 7.6 (1.7) 7.5 (1.3) 7.2 (1.1) 7.4 (1.3) 7.3 (1.3) 7.0 (1.6) 7.3 (1.4) 7.7 (1.8) 6.7 (1.4) 0.8251 7.2 (1.3) 7.1 (1.3) 0.1510
 No LDL-C increase group (group NI) 7.5 (2.0) 8.0 (1.6) 7.5 (2.0) 7.8 (1.1) 7.5 (1.9) 7.4 (1.1) 7.2 (1.3) 8.1 (0.8) 7.4 (2.3) 0.9534 7.5 (1.5) 7.4 (1.6) 0.1561
P*** 0.7866 0.3344 0.5476 0.5551 0.6126 0.6060 0.7508 0.6851 0.3621   0.5568 0.4819  
  1. P<0.05 was considered statistically significant. *, Statistical analysis was done using the Kruskal-Wallis test or ANOVA. aMean value of 3 measurements before pemafibrate; bMean value of 6 measurements after pemafibrate. **, Statistical analysis was done using Wilcoxon signed-rank test or paired t-test. ***, Statistical analysis between 2 groups I and NI was done using the Mann-Whitney U test or t-test. LDL-C Low density lipoprotein cholesterol, HbA1c Glycated hemoglobin